Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
Status:
Recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing
mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their
index admission to hospital.